Somalogic Inc (SLGC) Stock
SLGC is no longer traded. Somalogic was delisted from the Nasdaq in January 2024.
Prices on this page are historical; the last trade was January 5, 2024 at $2.10.
Somalogic stock price history
SLGC final trading statistics
- Final close
- $2.10
- Final trading day
- Jan 5, 2024
- Market cap at delisting
- $396.23M
- Shares outstanding
- 188.68M
- Final 52-week range
- $1.73 – $3.79
- Avg. volume (final 3 mo.)
- 2,269,949
- All-time high (split-adj.)
- $14.28 · Nov 2021
- All-time low (split-adj.)
- $1.76 · Oct 2023
- Return since IPO
- -84.8%
- Beta
- 1.64
- Book value / share
- $2.63
- Price / book
- 0.80
Somalogic annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $81.72M | -$130.4M | — |
| FY2022 | $97.67M | -$109.2M | -$0.59 |
| FY2021 | $81.63M | -$86.3M | -$1.12 |
| FY2020 | $55.89M | -$71.4M | — |
| FY2019 | $32.19M | -$57.0M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Somalogic Inc
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.
Somalogic stock FAQ
What happened to Somalogic stock?
Somalogic stock was delisted from the Nasdaq. Its final close was $2.10 on January 5, 2024.
Is SLGC stock still trading?
No. SLGC was delisted from the Nasdaq in January 2024 and no longer trades on a U.S. exchange.
What was the last price of SLGC stock?
SLGC closed at $2.10 on its final trading day, January 5, 2024, for a market value of about $396.23M.
What were Somalogic's revenue and earnings in its last full fiscal year?
Somalogic reported revenue of $81.72M and net income of -$130.4M in fiscal 2023, its last full year as a public company.
When did Somalogic go public?
Somalogic Inc stock began trading on April 23, 2021.